John Lunec

17.0k total citations · 1 hit paper
280 papers, 12.3k citations indexed

About

John Lunec is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, John Lunec has authored 280 papers receiving a total of 12.3k indexed citations (citations by other indexed papers that have themselves been cited), including 123 papers in Molecular Biology, 108 papers in Oncology and 54 papers in Cancer Research. Recurrent topics in John Lunec's work include Cancer-related Molecular Pathways (64 papers), Neuroblastoma Research and Treatments (36 papers) and DNA Repair Mechanisms (26 papers). John Lunec is often cited by papers focused on Cancer-related Molecular Pathways (64 papers), Neuroblastoma Research and Treatments (36 papers) and DNA Repair Mechanisms (26 papers). John Lunec collaborates with scholars based in United Kingdom, United States and Netherlands. John Lunec's co-authors include Marcus S. Cooke, Mark D. Evans, Miral Dizdaroğlu, David R. Blake, Deborah A. Tweddle, Helen R. Griffiths, David E. Neal, Tiago L. Duarte, Andrew D.J. Pearson and Nalini Mistry and has published in prestigious journals such as Nature, The Lancet and Nucleic Acids Research.

In The Last Decade

John Lunec

280 papers receiving 11.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Oxidative DNA damage: mechanisms, mutation, and disease

2003 2.5k citations Marcus S. Cooke, Mark D. Evans et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
John Lunec	5.9k	2.7k	2.1k	1.7k	1.3k	280	12.3k
Marcel Leist	10.1k 1.7×	1.5k 0.6×	1.3k 0.6×	1.2k 0.7×	797 0.6×	291	19.4k
Umberto Dianzani	5.9k 1.0×	2.0k 0.7×	1.1k 0.5×	473 0.3×	1.2k 0.9×	462	16.6k
Chris Reutelingsperger	9.4k 1.6×	1.3k 0.5×	1.4k 0.7×	540 0.3×	1.1k 0.8×	260	18.4k
Larry W. Oberley	11.0k 1.9×	1.7k 0.6×	2.9k 1.4×	459 0.3×	2.2k 1.7×	227	20.5k
Daret K. St. Clair	6.8k 1.2×	1.6k 0.6×	1.7k 0.8×	467 0.3×	849 0.6×	175	12.9k
Vladimir A. Tyurin	7.2k 1.2×	742 0.3×	1.4k 0.7×	745 0.4×	970 0.7×	189	12.4k
Xiao-Ming Yin	9.6k 1.6×	1.5k 0.6×	1.4k 0.7×	553 0.3×	589 0.4×	96	16.2k
Tetsuro Ishii	13.8k 2.4×	967 0.4×	1.3k 0.6×	541 0.3×	1.2k 0.9×	152	19.8k
Vasilis Vasiliou	7.0k 1.2×	2.4k 0.9×	2.5k 1.2×	370 0.2×	437 0.3×	264	14.8k
Yulia Y. Tyurina	7.7k 1.3×	630 0.2×	1.5k 0.7×	843 0.5×	965 0.7×	206	14.0k

Countries citing papers authored by John Lunec

Since Specialization

Citations

This map shows the geographic impact of John Lunec's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Lunec with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Lunec more than expected).

Fields of papers citing papers by John Lunec

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Lunec. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Lunec. The network helps show where John Lunec may publish in the future.

Co-authorship network of co-authors of John Lunec

This figure shows the co-authorship network connecting the top 25 collaborators of John Lunec. A scholar is included among the top collaborators of John Lunec based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Lunec. John Lunec is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wallis, Jonathan P., Helen Marr, Scott Marshall, et al.. (2025). Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for Treating TP53 Wild-Type Chronic Lymphocytic Leukemia. Cancers. 17(2). 274–274. 2 indexed citations

Nakjang, Sirintra, Jonathan P. Wallis, Helen Marr, et al.. (2024). RNA Sequencing Reveals Candidate Genes and Pathways Associated with Resistance to MDM2 Antagonist Idasanutlin in TP53 Wild-Type Chronic Lymphocytic Leukemia. Biomedicines. 12(7). 1388–1388. 4 indexed citations

Blair, Helen J., Anthony V. Moorman, Olaf Heidenreich, et al.. (2023). Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia. Cancer Cell International. 23(1). 202–202. 2 indexed citations

Ciardullo, Carmela, Jonathan P. Wallis, Helen Marr, et al.. (2023). Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition. International Journal of Molecular Sciences. 24(3). 2410–2410. 11 indexed citations

Wallis, Jonathan P., Helen Marr, Scott Marshall, et al.. (2023). SF3B1 Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic Leukemia. International Journal of Molecular Sciences. 24(14). 11335–11335. 7 indexed citations

Chen, Lindi, Fabio Pastorino, Philip Berry, et al.. (2018). Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma. International Journal of Cancer. 144(12). 3146–3159. 26 indexed citations

Nakjang, Sirintra, et al.. (2016). Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner. Molecular Cancer Therapeutics. 15(3). 379–391. 41 indexed citations

Chen, Lindi, Nunzio Iraci, Samuele Gherardi, et al.. (2010). p53 Is a Direct Transcriptional Target of MYCN in Neuroblastoma. Cancer Research. 70(4). 1377–1388. 98 indexed citations

Pinkney, Michael, et al.. (2009). A Monoclonal Antibody for Detection of Folylpolyglutamate Synthetase in Paraffin Embedded Tissues. Hybridoma. 28(6). 415–421. 1 indexed citations

10.

Kelly, Seamus B., et al.. (2007). The predictive value of p53 and p33^ING1b in patients with Dukes'C colorectal cancer. Colorectal Disease. 10(4). 344–351. 13 indexed citations

11.

Ahmed, Shafiq U., Claire Hutton, & John Lunec. (2004). Increased susceptibility of MDM2 amplified cell lines to MDM2-p53 inhibitors is associated with a high turnover of MDM2 and p53. Cancer Research. 64. 695–695. 2 indexed citations

12.

Cooke, Marcus S., Rosamund Dove, Rafał Różalski, et al.. (2004). Diet does not influence levels of urinary 8-hydroxy-2 '- deoxyguanosine or 8-hydroxyguanine in humans. Mutagenesis. 19(6). 1 indexed citations

13.

Angus, Brian, et al.. (2002). Comparative Assessment Expression of the Inhibitor of Growth 1 Gene ( ING1 ) in Normal and Neoplastic Tissues. PubMed. 21(1). 1–10. 29 indexed citations

14.

Cooke, Marcus S., et al.. (2000). Angiotensin II inhibits oxidised DNA repair in human vascular smooth muscle cells. Journal of Hypertension. 18. 207. 1 indexed citations

15.

Lunec, John & Helen R. Griffiths. (2000). Measuring in vivo oxidative damage : a practical approach. Wiley eBooks. 28 indexed citations

16.

Angus, Brian, et al.. (1998). Cyclin D1 expression in transitional cell carcinoma (TCC) of the bladder: Correlation with WAF1, p53 and Ki67.. The Journal of Urology. 159. 281–281. 3 indexed citations

17.

Griffiths, T.R. Leyshon, et al.. (1998). Chemotherapy and muscle-invasive bladder cancer: Assessment of p53 immuno-reactivity (IR) as a predictor of response. British Journal of Cancer. 78. 20–20. 1 indexed citations

18.

Lunec, John, et al.. (1992). Human lymphoblastoid cells with acquired resistance to C2-desamino-C2-methyl-N10-propargyl-5,8-dideazafolic acid: a novel folate-based thymidylate synthase inhibitor.. PubMed. 52(5). 1137–43. 22 indexed citations

19.

Lunec, John, et al.. (1983). Effect of Membrane Fatty Acid Changes on the Radiation Sensitivity of Human Lymphoid Cells. International Journal of Radiation Biology and Related Studies in Physics Chemistry and Medicine. 43(4). 363–378. 23 indexed citations

20.

Lunec, John, et al.. (1983). Post-irradiation Inhibition of Scheduled DNA Synthesis and Stimulation of ADP-ribosylation in Sensitive and Resistant L5178Y Murine Lymphoma Cells. International Journal of Radiation Biology and Related Studies in Physics Chemistry and Medicine. 44(6). 645–651. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact